Grupo Aeroportuario del Pacifico Reports in January 2023 a Passenger Traffic Increase of 33.1% Compared to 2022
February 03, 2023 16:59 ET
|
Grupo Aeroportuario del Pacífico, S.A.B. de C.V.
GUADALAJARA, Mexico, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger...
Cybrexa Strengthens Drug Development Capabilities with the Addition of Laurie Kenvin to the Company’s Leadership Team and Nick Saccomano to the SAB
February 01, 2023 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Cleveland Golf Releases All-New CBX Full-Face 2 With Largest CBX Face Ever
January 18, 2023 12:00 ET
|
Cleveland Golf
HUNTINGTON BEACH, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- CLEVELAND GOLF®, an industry leader in wedge design and innovation, announces the release of the all-new CBX Full-Face 2 Wedge. The CBX...
Grupo Aeroportuario del Pacifico Reports in December 2022 a Passenger Traffic Increase of 18.6% Compared to 2019 (Increase of 18.8% Compared to 2021)
January 04, 2023 18:59 ET
|
Grupo Aeroportuario del Pacífico, S.A.B. de C.V.
GUADALAJARA, Mexico, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger...
Cybrexa Therapeutics Announces the Appointment of Michael N. Needle, MD, as Senior Vice President and Chief Medical Officer
December 15, 2022 07:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Grupo Aeroportuario del Pacifico Reports in November 2022 a Passenger Traffic Increase of 22.4% Compared to 2019 (Increase of 22.3% Compared to 2021)
December 05, 2022 17:08 ET
|
Grupo Aeroportuario del Pacífico, S.A.B. de C.V.
GUADALAJARA, Mexico, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger...
Grupo Aeroportuario del Pacifico Reports in October 2022 a Passenger Traffic Increase of 22.1% Compared to 2019 (Increase of 21.6% Compared to 2021)
November 04, 2022 20:45 ET
|
Grupo Aeroportuario del Pacífico, S.A.B. de C.V.
GUADALAJARA, Mexico, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger...
Cybrexa Therapeutics Presents Findings from First-in-Human Study of CBX-12 as a Plenary Oral Presentation at 34th EORTC-NCI-AACR Symposium
October 28, 2022 09:25 ET
|
Cybrexa Therapeutics
Positive FIH safety and tolerability data supports advancing CBX-12 into multiple Phase II studiesResults show early signs of efficacy with a favorable safety profile NEW HAVEN, Conn., Oct. 28, 2022...
Cybrexa Therapeutics在第34届EORTC-NCI-AACR研讨会上作全体口头报告，介绍CBX-12的首次人类研究结果
October 28, 2022 09:25 ET
|
Cybrexa Therapeutics
积极的FIH安全性和耐受性数据支持将CBX-12推进到多项II期研究结果显示疗效的早期迹象，伴有良好的安全性 康涅狄格州纽黑文, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Cybrexa...
Cybrexa Therapeutics Presents Findings from First-in-Human Study of CBX-12 as a Plenary Oral Presentation at 34th EORTC-NCI-AACR Symposium
October 28, 2022 09:25 ET
|
Cybrexa Therapeutics
Positive FIH safety and tolerability data supports advancing CBX-12 into multiple Phase II studiesResults show early signs of efficacy with a favorable safety profile NEW HAVEN, Conn., Oct. 28, 2022...